RxDoctor Payments Data

Jodie Hall

Family · Maple Hill, NCNPI 1851984082

Payments from drug & device makers

$1,188in general payments, 2019–2025

Across 45 payments — averaging $26.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$586
  • Bayer$245
  • Lilly USA, LLC$115
  • Exact Sciences$58
  • Boehringer Ingelheim$53
  • GSK$40
  • plus $92 from 4 others

What the payments were for

  • Food & beverage$1,188100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,188 in reported general payments places this provider in the 70th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$17,138
Medicare patients
161
Services billed
290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$32,765
FarxigaDapagliflozin Propanediol23$29,534
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$14,238
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$9,377
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,544
Albuterol Sulfate HfaAlbuterol Sulfate47$1,132
Omeprazole22$429
Gabapentin26$417
Atorvastatin Calcium72$413
Potassium Chloride30$407
Tamsulosin Hcl20$371
Fluticasone Propionate42$352
Metoprolol Succinate12$272
Levothyroxine Sodium46$269
Pregabalin19$236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$586$38,91037 claims
Novo NordiskOzempic$32$32,76531 claims
GSKTrelegy Ellipta$40$14,23816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,522 family providers in North Carolina.

Other family in Maple Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →